-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma to present four preclinical combination-therapy studies at AACR 2026

PUBT·04/19/2026 23:10:19
Listen to the news
Ascentage Pharma to present four preclinical combination-therapy studies at AACR 2026
  • Ascentage Pharma scheduled four preclinical oncology studies for poster presentation at AACR 2026 in San Diego, April 17-22, 2026.
  • New data to be presented indicate olverembatinib showed anti-tumor activity in preclinical endometrial cancer models, with stronger effects when combined with standard chemotherapy.
  • Separate preclinical work to be presented suggests olverembatinib could enhance responses in mantle cell lymphoma when paired with BTK inhibitor acalabrutinib, supporting a potential combination strategy.
  • APG-2449 preclinical results to be presented point to improved activity when added to MAPK-pathway blockade in BRAF V600E-mutant tumor models, addressing resistance seen with current regimens.
  • APG-5918 findings to be presented show synergistic anti-cancer effects in small-cell lung cancer models when combined with topoisomerase I inhibitors, backing plans for combination-focused clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260420-12111214), on April 19, 2026, and is solely responsible for the information contained therein.